Search

M2 PRESSWIRE-December 9, 2024-: 'Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation - AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances' (C)1994-2024 M2 COMMUNICATIONS RDATE:06122024 The healthcare and technology sectors [...]

- New Positive Clinical Data Demonstrate Momentum on Investigational Once-Daily, Once-Weekly and Twice-Yearly Dosing Strategies - - Key Findings from Studies Evaluating Potential Future Long-Acting Combination Regimens Affirm Commitment to [...]

Gilead Sciences, Inc. Joins Collaborative R&D Consortia PHILADELPHIA -- TransCelerate BioPharma Inc. (TransCelerate), announced today an expansion of its membership and appointment of the organization's Chief Operating Officer. Gilead Sciences, [...]

Gilead Sciences Inc announced on 16 Oct 2023 its upcoming participation in the 19th European AIDS Conference (EACS) to be held in Warsaw, Poland on 18-21 Oct 2023. As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programmes. The research that will be presented at EACS 2023, along with symposia led by Gilead, reflects the company's person-centred approach to advancing scientific innovation and underscores its focus on community partnership to help end the HIV epidemic. At EACS 2023, Gilead will present new findings on long-acting HIV treatment strategies, including outcomes from multiple studies evaluating twice-yearly lenacapavir, Gilead's first-in-class, long-acting HIV-1 capsid inhibitor. These findings will include insights, experience and perspectives from healthcare professionals and study coordinators from CAPELLA, an ongoing Phase 2/3 registrational study designed to evaluate the antiviral activity and safety of twice-yearly lenacapavir administered as a subcutaneous injection in adults with multi-drug resistant HIV who are heavily treatment experienced. Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy's resistance profile. Lenacapavir has exhibited no overlapping resistance in vitro with any currently approved antiretroviral therapy. Original source: Gilead, website: http://www.gilead.com/, Copyright Gilead 2023., joint venture; research and development; anti-HIV drugs; lenacapavir; Gilead [...]

Gilead Sciences, Inc. announced the upcoming presentation of new clinical and real-world data from the companys HIV, COVID-19 and viral hepatitis research and development programs at the 30th Conference on [...]

Gilead Sciences Inc announced on 14 Feb 2023 the upcoming presentation of new clinical and real-world data from the company's HIV, COVID-19 and viral hepatitis research and development programmes at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) on 19-22 Feb 2023. Seventy abstracts, including late-breaking data, demonstrate Gilead's continued expertise and leadership in virology with a commitment to advance the next wave of scientific discovery to treat, prevent, cure and help eradicate viral diseases. Gilead is committed to continuous scientific discovery to provide solutions for the evolving needs of people affected by HIV around the world, with the goal of ending the HIV epidemic for everyone, everywhere. At CROI 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company's continued pursuit of an HIV cure. HIV treatment research and development data include proof-of-concept Phase 1b data on the safety and efficacy profile of lenacapavir in combination with investigational broadly neutralizing antibodies (bNAbs) - teropavimab and zinlirvimab - dosed twice-yearly in virologically suppressed adults for the treatment of HIV. Additionally, Gilead will present data from a preclinical in vivo assessment of a single subcutaneous administration of lenacapavir for pre-exposure prophylaxis (PrEP). Gilead will present data that reinforce the critical role Veklury (remdesivir) plays as the antiviral standard of care for the treatment of hospitalized patients with COVID-19. Real-world insights on Veklury's use will provide important, up-to-date evidence from large, hospitalized populations - including patients with immunocompromised conditions - across different periods of the pandemic and different variants of concern. Additionally, Gilead will present a new in vitro analysis that evaluates the antiviral activity of Veklury against common variants of concern, and data assessing the resistance profile of Veklury and other antiviral compounds. Gilead will present new data from the ALLIANCE trial, which is an ongoing Phase 3 trial evaluating Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) versus dolutegravir (50 mg, DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection who are initiating treatment. The sub-analysis of Week 48 results complements the initial data presented at the 24th International AIDS Conference (AIDS 2022), with a focus on the HBV outcomes in this coinfected population. Original source: Gilead, website: http://www.gilead.com/, Copyright Gilead 2023., research and development; anti-HIV drugs; antiviral agents; bictegravir; Biktarvy; dolutegravir; emtricitabine; hepatitis B treatments; lenacapavir; monoclonal antibodies; remdesivir; respiratory disease treatments; tenofovir; tenofovir alafenamide; tenofovir disoproxil fumarate; teropavimab; therapeutic antibodies; [...]

DUBLIN: Research and Markets has issued the following news release: The 'Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update' report has [...]

DUBLIN -- The 'Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update' report has been added to ResearchAndMarkets.com's offering. This report provides [...]

M2 PRESSWIRE-September 30, 2022-: 2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others (C)1994-2022 M2 COMMUNICATIONS RDATE:30092022 The [...]

Latest HIV Clinical Research and Development Data Drive the Next Wave of Innovation in Treatment, Prevention and Reaches Towards a Cure Key Initiatives Highlight Role of Catalytic Collaboration to Help [...]

Late-Breaking TROPiCS-02 Study Results in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients to be Featured in ASCO Press Program New Sub-Analysis from Kites ZUMA-7 CAR T-cell Therapy Study in Patients [...]

Gilead Sciences Inc announced the upcoming presentation of new data from the company's HIV and COVID-19 research and development programmes at the 29th Conference on Retroviruses and Opportunistic Infections (virtualCROI 2022) taking place on 12-16 Feb 2022. The data reflect Gilead's enduring dedication to advancing global health through scientific innovation by addressing some of the world's most challenging viruses. Gilead's commitment to inclusive research facilitates the discovery and development of person-centred therapeutic options that address the evolving needs of a broad range of individuals. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world, with the goal of ending the HIV epidemic for everyone, everywhere. At CROI 2022, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company's continued pursuit of an HIV cure. The five-year cumulative outcomes of two Phase 3 trials (Study 1489 and Study 1490), evaluating Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in treatment-naive people living with HIV (PLWH) will also be presented. These results demonstrate Biktarvy's long-term safety and tolerability profile, and sustained efficacy with a high barrier to resistance in participants who initiated treatment with the guidelines-recommended, once-daily, single-tablet regimen. Data presented from Gilead's cure research programme uncover insights to further the collective scientific knowledge on potential pathways to achieve a functional cure or long-term viral remission in the absence of antiretroviral therapy for PLWH. Additionally, at CROI 2022, Gilead will present new prevention research using data from the DISCOVER trial to evaluate the performance of different recency assays to calculate the background HIV incidence, or how many new HIV infections are occurring in a region. Recency assays have been proposed as the primary methodology to evaluate the efficacy of novel PrEP agents in next-generation PrEP clinical trials. Original source: Gilead, website: http://www.gilead.com/, Copyright Gilead 2022., research and development; anti-HIV drugs; bictegravir; Biktarvy; emtricitabine; tenofovir; tenofovir alafenamide; Gilead [...]

Gilead Sciences, Inc. announced the companys upcoming contributions to the 11th International AIDS Society (IAS) Conference on HIV Science, taking place virtually from July 18-21. Thirty-one abstracts reflect Gileads ongoing [...]

FOSTER CITY: Gilead Sciences, Inc. has issued the following news release: Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company's upcoming contributions to the 11th International AIDS Society (IAS) Conference [...]

--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company's upcoming contributions to the 11th International AIDS Society (IAS) Conference on HIV Science, taking place virtually from July 18-21. Thirty-one abstracts [...]

SAN JOSE: TiE Silicon Valley has issued the following news release: TiEcon starts tomorrow for 3 days of unstoppable technology innovation topics-May 6-8, 2021. Featuring outstanding grand keynotes and an [...]

FinancialBuzz.com News Commentary NEW YORK, Sept. 8, 2020 /PRNewswire/ -- In response to the outbreak, governments around the world have focused their resources on curing the viral infection. Beyond the [...]

FinancialBuzz.com News Commentary NEW YORK, July 23, 2020 /PRNewswire/ -- The healthcare industry has made significant progress when it comes to efficiency and scope in the last several years, yet [...]

FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that new data from the company's HIV research and development program will be presented at the 23rd International AIDS Conference [...]

-Gilead Sciences, Inc. (Nasdaq:GILD) today announced that new data from the company's HIV research and development program will be presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) from [...]

SAN FRANCISCO, Feb 05, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- A coalition of strategic industry leaders - including Cardinal Health, Novartis Pharma AG, and Kite, a Gilead Company (Gilead [...]

2020 AUG 2 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- The current pandemic has created the need for new technologies in [...]